Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
LifeVantage Co. stock logo
LFVN
LifeVantage
$12.87
+1.7%
$12.90
$5.22
$27.38
$162.01M0.43144,895 shs65,622 shs
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
$2.26
-3.0%
$2.07
$1.46
$4.10
$15.05M0.1643,129 shs7,028 shs
NextCure, Inc. stock logo
NXTC
NextCure
$0.65
+5.7%
$0.43
$0.22
$1.82
$18.24M1.07109,703 shs244,685 shs
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
$0.34
+2.6%
$0.35
$0.25
$0.87
$8.46M0.1890,689 shs52,190 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
LifeVantage Co. stock logo
LFVN
LifeVantage
+0.56%-0.39%+6.66%-25.19%+66.01%
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
+1.30%+6.39%+12.24%+1.30%-17.08%
NextCure, Inc. stock logo
NXTC
NextCure
+11.79%+30.06%+41.68%-14.54%-56.67%
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
-6.33%-7.16%-9.90%-25.02%-53.89%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
LifeVantage Co. stock logo
LFVN
LifeVantage
4.1288 of 5 stars
3.50.01.72.73.51.71.3
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
1.6963 of 5 stars
0.03.00.04.11.90.81.3
NextCure, Inc. stock logo
NXTC
NextCure
4.6716 of 5 stars
3.55.00.04.33.01.71.3
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
4.744 of 5 stars
3.75.00.04.82.91.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
LifeVantage Co. stock logo
LFVN
LifeVantage
3.00
Buy$30.50136.99% Upside
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
2.00
HoldN/AN/A
NextCure, Inc. stock logo
NXTC
NextCure
3.00
Buy$3.50438.21% Upside
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
3.33
Buy$4.501,241.28% Upside

Current Analyst Ratings Breakdown

Latest MEIP, SNSE, NXTC, and LFVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$5.00
5/1/2025
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
3/28/2025
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$3.50 ➝ $4.00
3/28/2025
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00 ➝ $4.00
3/17/2025
NextCure, Inc. stock logo
NXTC
NextCure
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
LifeVantage Co. stock logo
LFVN
LifeVantage
$222.35M0.73$0.68 per share19.03$2.38 per share5.41
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
$65.30M0.23$5.14 per share0.44$3.32 per share0.68
NextCure, Inc. stock logo
NXTC
NextCure
N/AN/AN/AN/A$4.10 per shareN/A
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
N/AN/AN/AN/A$2.60 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
LifeVantage Co. stock logo
LFVN
LifeVantage
$2.94M$0.6922.98N/A3.46%34.29%15.04%8/27/2025 (Estimated)
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
$17.78M-$4.75N/AN/AN/AN/A-84.92%-67.53%N/A
NextCure, Inc. stock logo
NXTC
NextCure
-$62.72M-$1.76N/AN/AN/AN/A-62.50%-53.67%7/30/2025 (Estimated)
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
-$34.10M-$1.15N/AN/AN/AN/A-53.86%-46.91%8/5/2025 (Estimated)

Latest MEIP, SNSE, NXTC, and LFVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q3 2025
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
N/A-$0.39N/A-$0.39N/AN/A
5/6/2025Q3 2025
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
5/6/2025Q1 2025
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
-$0.21-$0.27-$0.06-$0.27N/AN/A
5/1/2025Q1 2025
NextCure, Inc. stock logo
NXTC
NextCure
-$0.40-$0.39+$0.01-$0.39N/AN/A
3/28/2025Q4 2024
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
-$0.27-$0.27N/A-$0.31N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.181.40%N/A26.09%3 Years
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
N/AN/AN/AN/AN/A
NextCure, Inc. stock logo
NXTC
NextCure
N/AN/AN/AN/AN/A
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
N/AN/AN/AN/AN/A

Latest MEIP, SNSE, NXTC, and LFVN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
LifeVantage Co. stock logo
LFVN
LifeVantage
quarterly$0.04501.5%5/30/20255/30/20256/13/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A
1.66
1.03
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
N/A
10.66
10.66
NextCure, Inc. stock logo
NXTC
NextCure
N/A
9.07
9.07
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
N/A
8.84
8.84

Institutional Ownership

CompanyInstitutional Ownership
LifeVantage Co. stock logo
LFVN
LifeVantage
35.32%
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
52.38%
NextCure, Inc. stock logo
NXTC
NextCure
42.65%
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
10.50%

Insider Ownership

CompanyInsider Ownership
LifeVantage Co. stock logo
LFVN
LifeVantage
20.65%
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
3.12%
NextCure, Inc. stock logo
NXTC
NextCure
17.90%
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
23.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
LifeVantage Co. stock logo
LFVN
LifeVantage
26012.59 million9.96 millionOptionable
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
1006.66 million6.46 millionOptionable
NextCure, Inc. stock logo
NXTC
NextCure
9028.05 million24.28 millionOptionable
Sensei Biotherapeutics, Inc. stock logo
SNSE
Sensei Biotherapeutics
4025.21 million19.62 millionNot Optionable

Recent News About These Companies

Brokers Issue Forecasts for SNSE Q2 Earnings
Sensei Rockets on FY ’24 Results
Sensei Rockets on FY ’24 Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

LifeVantage stock logo

LifeVantage NASDAQ:LFVN

$12.87 +0.22 (+1.74%)
As of 04:00 PM Eastern

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

MEI Pharma stock logo

MEI Pharma NASDAQ:MEIP

$2.26 -0.07 (-3.00%)
As of 04:00 PM Eastern

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

NextCure stock logo

NextCure NASDAQ:NXTC

$0.65 +0.04 (+5.69%)
As of 04:00 PM Eastern

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

Sensei Biotherapeutics stock logo

Sensei Biotherapeutics NASDAQ:SNSE

$0.34 +0.01 (+2.63%)
As of 04:00 PM Eastern

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.